comparemela.com

Direct Dispense News Today : Breaking News, Live Updates & Top Stories | Vimarsana

RVL Pharmaceuticals plc Reports Fourth Quarter and Full Year 2022 Financial Results; Provides Commercial Update

20.03.2023 - - RVLP records exceptional year-over-year growth with UPNEEQ launch into the medical aesthetics market - - Full year 2022 total revenues of $49.7 million, an increase of $32.2 million, or 184%, over 2021 - - Full year 2022 UPNEEQ net product sales .

RVL Pharmaceuticals plc Reports First Quarter 2022 Financial Results; Provides Commercial Update

12.05.2022 - First quarter 2022 UPNEEQ net product sales of $5.9 million; 90% growth over fourth quarter 2021 First quarter 2022 total revenues of $21.4 million, inclusive of $15.5 million from Santen License Agreement, with related cash receipt in April 2022 .

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.